Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Sees Better Days Ahead With The Launch Of Valtrex Generic In U.S.

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - There is finally some positive news for India's Ranbaxy as it launched the generic versions of GlaxoSmithKline's herpes treatment Valtrex (valacyclovir) Nov. 25 in the U.S

You may also be interested in...



Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains

MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India

Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains

MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India

Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To U.S. Ohm Labs After FDA Crackdown

Billings for valacyclovir, generic Valtrex, which Ranbaxy shifted earlier to its New Jersey affiliate, reached $100 million within the first week of the U.S. launch.

Related Content

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel